Literature DB >> 12021544

Recombinant marker allergens: diagnostic gatekeepers for the treatment of allergy.

Lili Kazemi-Shirazi1, Verena Niederberger, Birgit Linhart, Jonas Lidholm, Dietrich Kraft, Rudolf Valenta.   

Abstract

During the past decade an increasing number of recombinant allergens have become available, representing a significant proportion of the epitope complexity of natural allergen extracts. Component-resolved diagnosis with recombinant allergens reveals the antibody reactivity profile of allergic patients and identifies the disease-eliciting allergen molecules. This article exemplifies how recombinant allergen molecules with high cross-reactive potential can be used as marker allergens to identify allergic patients who are cross-sensitized to a variety of allergen sources. It further demonstrates how the use of allergens with a restricted distribution in a certain group of allergen sources may allow the identification of patients who have been genuinely sensitized by a particular allergen molecule. Drawing from those examples, it is suggested how diagnostic tests based on such recombinant marker allergens may be used to improve the choice and monitoring of currently available forms of specific immunotherapy. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12021544     DOI: 10.1159/000057742

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  26 in total

Review 1.  Biology of tree pollen allergens.

Authors:  Nadine Mothes; Rudolf Valenta
Journal:  Curr Allergy Asthma Rep       Date:  2004-09       Impact factor: 4.806

Review 2.  [Microarray technique for component resolved diagnosis (CRD) in type-I allergies. An innovative technology at the border between research tool and routine diagnostics].

Authors:  L Klimek; D Vetter; L von Bernus; C Thorn
Journal:  HNO       Date:  2011-10       Impact factor: 1.284

Review 3.  [Molecular-allergological aspects of allergen-specific immunotherapy].

Authors:  Uta Jappe
Journal:  Hautarzt       Date:  2017-04       Impact factor: 0.751

4.  Immunoglobulin E reactivity of recombinant allergen Tyr p 13 from Tyrophagus putrescentiae homologous to fatty acid binding protein.

Authors:  Kyoung Yong Jeong; Woo Kyung Kim; Jae Sik Lee; Jongweon Lee; In-Yong Lee; Kyu-Earn Kim; Jung Won Park; Chein-Soo Hong; Han-Il Ree; Tai-Soon Yong
Journal:  Clin Diagn Lab Immunol       Date:  2005-05

5.  Panallergens and their impact on the allergic patient.

Authors:  Michael Hauser; Anargyros Roulias; Fátima Ferreira; Matthias Egger
Journal:  Allergy Asthma Clin Immunol       Date:  2010-01-18       Impact factor: 3.406

6.  Proteolytically inactive per a 10 allergen of Periplaneta americana modulates Th2 response and enhances IL-10 in mouse model.

Authors:  Deepsikha Srivastava; Amit Kumar Mehta; Naveen Arora; Shailendra Nath Gaur; Bhanu Pratap Singh
Journal:  J Clin Immunol       Date:  2010-01-14       Impact factor: 8.317

7.  Polysensitisation to pollen due to profilin and calcium-binding protein: distribution of IgE antibodies to marker allergens in grass and birch pollen allergic rhinitis patients in southern Germany.

Authors:  G Muehlmeier; H Maier
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-07-02       Impact factor: 2.503

8.  Greater Real-Life Diagnostic Efficacy of Allergen Molecule-Based Diagnosis for Prescription of Immunotherapy in an Area with Multiple Pollen Exposure.

Authors:  Ulbosin Saltabayeva; Victoria Garib; Marina Morenko; Rafail Rosenson; Zhanat Ispayeva; Madina Gatauova; Loreta Zulus; Alexander Karaulov; Felix Gastager; Rudolf Valenta
Journal:  Int Arch Allergy Immunol       Date:  2017-06-28       Impact factor: 2.749

9.  Molecular allergology approach to allergic diseases in the paediatric age.

Authors:  Claudia Alessandri; Danila Zennaro; Alessandra Zaffiro; Adriano Mari
Journal:  Ital J Pediatr       Date:  2009-10-05       Impact factor: 2.638

Review 10.  Multiple grass mixes as opposed to single grasses for allergen immunotherapy in allergic rhinitis.

Authors:  K Gangl; V Niederberger; R Valenta
Journal:  Clin Exp Allergy       Date:  2013-11       Impact factor: 5.018

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.